Atara In Disarray As Shares Sink On Ebvallo CRL

The Pierre Fabre-partnered allogeneic T-cell immunotherapy is already available in Europe but hopes of a US approval have been hit by a complete response letter citing problems at a third-party manufacturing facility.

Delay
• Source: Shutterstock

Atara Biotherapeutics' hopes of getting Ebvallo approved soon in the US have been dashed after the Food and Drug Administration rejected the off-the-shelf cell therapy due to manufacturing issues, sending the US biotech’s shares through the floor and threatening its survival.

Ebvallo (tabelecleucel), which was approved by the European Medicines Agency in December 2022 for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell Therapies

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

More from Therapy Areas

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.